Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balovaptan PK in Hepatic Impairment
NCT03912350Phase 1Withdrawn
- Sponsor
- Roche
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of balovaptan in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Roche. Primary endpoints: Plasma concentration of balovaptan at Day 14, Plasma concentration of M2 metabolite at Day 14 and 12 more. Planned start Jun 2022; status: withdrawn.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03912350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912350.